Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why
Corcept (CORT) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?
The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept Therapeutics: A Most Promising And Compelling Biotech
Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's robust financials, strong profitability, and near-monopolistic position in a niche market underscore its investment potential despite legal risks and reliance on a single product. The company's innovative pipeline, especially Relacorilant, could significantly expand its market reach and diversify revenue streams, driving strong future growth.
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept Shares Rise More Than 60% in Three Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.
3 Reasons Growth Investors Will Love Corcept (CORT)
Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable
Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
